FDMT vs. AUTL, TARS, SRRK, ADAP, VIR, ADMA, INBX, BCRX, NMRA, and IMTX
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Autolus Therapeutics (AUTL), Tarsus Pharmaceuticals (TARS), Scholar Rock (SRRK), Adaptimmune Therapeutics (ADAP), Vir Biotechnology (VIR), ADMA Biologics (ADMA), Inhibrx (INBX), BioCryst Pharmaceuticals (BCRX), Neumora Therapeutics (NMRA), and Immatics (IMTX). These companies are all part of the "biological products, except diagnostic" industry.
Autolus Therapeutics (NASDAQ:AUTL) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership.
Autolus Therapeutics has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.87, indicating that its stock price is 187% more volatile than the S&P 500.
72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 10.7% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Autolus Therapeutics currently has a consensus target price of $8.16, suggesting a potential upside of 93.82%. 4D Molecular Therapeutics has a consensus target price of $44.22, suggesting a potential upside of 82.36%. Given 4D Molecular Therapeutics' higher possible upside, research analysts plainly believe Autolus Therapeutics is more favorable than 4D Molecular Therapeutics.
Autolus Therapeutics has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -436.30%. Autolus Therapeutics' return on equity of -34.14% beat 4D Molecular Therapeutics' return on equity.
Autolus Therapeutics received 185 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. Likewise, 67.08% of users gave Autolus Therapeutics an outperform vote while only 64.71% of users gave 4D Molecular Therapeutics an outperform vote.
4D Molecular Therapeutics has higher revenue and earnings than Autolus Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Autolus Therapeutics had 1 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 8 mentions for Autolus Therapeutics and 7 mentions for 4D Molecular Therapeutics. Autolus Therapeutics' average media sentiment score of 0.82 beat 4D Molecular Therapeutics' score of 0.40 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.
Summary
Autolus Therapeutics and 4D Molecular Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
